Beyond the Microscope: Unlocking the Secrets of Ependymoma Through Molecular Insights
"Discover how advancements in molecular biology are transforming our understanding of ependymoma, paving the way for targeted treatments and improved outcomes."
Ependymoma (EPN) is a tumor of the central nervous system that affects both children and adults. In children, these tumors typically arise in the brain, either above the tentorium cerebelli (supratentorial) or in the posterior fossa, which includes the cerebellum and brainstem. Spinal ependymomas are more commonly seen in adults. Currently, the primary treatment for ependymoma involves surgery to remove as much of the tumor as safely possible, followed by radiation therapy.
The role of chemotherapy in treating ependymoma remains a topic of debate, and it is being investigated in ongoing clinical trials. While there are currently no approved targeted therapies for ependymoma, research efforts are focused on identifying new molecular targets. As a result, survival rates have seen modest improvement of 80% in the last decade, with survivors suffering from the debilitating side effects of treatment-related surgery and radiation.
Traditionally, histopathology, or the microscopic examination of tissue samples, has been used to diagnose and assess the risk associated with ependymoma. However, this approach has not been reliable in predicting patient survival, except for certain WHO Grade I tumors like subependymomas. The inconsistency in histopathologic grading has driven researchers and clinicians to explore more sensitive and unbiased molecular approaches to identify reliable prognostic markers and understand the molecular biology of ependymoma, with the goal of developing targeted therapies.
The Burden of Ependymoma
Ependymomas are a broad group of glial tumors with ependymal differentiation that typically arise from or near the lining of the brain's ventricles or the spinal cord's central canal. They can occur in both the brain and spine, forming initially in ependymal cells located in the fluid-filled spaces of the brain or within the spinal cord. The average five-year survival rate for ependymoma is reported at approximately 83 percent. While this figure suggests relatively favorable outcomes overall, survival varies significantly by tumor grade, stage, location, and extent of disease.
Current Treatment Paradigms and Gaps
Current standard treatment for pediatric ependymomas that are completely resected does not include chemotherapy as a primary therapy component. Modern ependymoma diagnosis relies on sophisticated imaging techniques that provide detailed visualization of these tumors. The BIOMECA study has highlighted the importance of standardizing ependymoma biomarkers across clinical trials, noting that core and core plus testing approaches can help guide diagnosis in resource-limited settings. Stage 3 ependymomas are recognized as particularly aggressive, underscoring the need for comprehensive staging and personalized treatment planning.
Origins and Evolving Understanding
Ependymoma is classified as a glioma of ependymal origin, with Stanford Medicine identifying three distinct kinds of the disease. While ependymoma rarely runs in families, some diagnosed cases may have a genetic component. Advances such as single-cell RNA sequencing have begun to reveal the different cells of origin for these tumors, helping explain why some ependymomas are more aggressive while others are more treatable. These molecular insights represent a significant shift from purely histological classification toward biologically grounded subtyping.
Decoding Ependymoma: A Molecular Revolution
Thanks to advanced technologies in transcriptomics, genomics, and epigenomics (collectively known as '-omics'), we are now gaining unprecedented insights into ependymoma. These approaches have revealed that ependymomas are not a single entity but rather a collection of distinct subgroups, each with unique clinical and biological characteristics. The most comprehensive analysis to date has identified at least nine molecular subgroups.
- Histopathologic grading of Grade II or III EPN outside of clinical trials should not be used to risk stratify future patients.
- Ependymoma is composed of at least nine different diseases.
- Frequent gene fusions define supratentorial ependymoma, namely, C11ORF95-RELA.
- '-omics'-based tumor characterization will continue to unravel the molecular basis of ependymoma and its subgroups.
Emerging Therapies and Research Networks
The CERN Foundation, established as a collaborative network of scientists and neuro-oncologists, has been dedicated to advancing ependymoma research and raising awareness, with Ependymoma Awareness Day first recognized in 2012. New targeted agents and immunotherapies are being explored specifically for recurrent ependymoma patients, reflecting a growing emphasis on precision medicine approaches. Recent reviews summarize significant molecular advances in the diagnosis and treatment of intracranial ependymomas, spanning surgery, radiation therapy, and systemic therapies. These developments signal a transition toward more molecularly informed treatment strategies.
Complexity Beyond Simple Classification
Ependymoma is now understood to be a molecularly heterogeneous disease, divided into at least nine distinct molecular subtypes based on DNA methylation and gene expression profiling. This complexity challenges earlier, simpler classification systems. In pediatric cases, ependymomas are typically intracranial, with the floor of the fourth ventricle being a common location, while in adults they are more frequently spinal. Posterior fossa ependymomas, a common subtype, present symptoms depending on tumor size, location, and whether they obstruct cerebrospinal fluid flow, further complicating diagnosis and treatment.
Ependymoma Among Brain Tumors
Pediatric ependymomas comprise biologically distinct tumor entities characterized by different epigenetics, age distribution, localization, and prognosis. Although both ependymomas and astrocytomas are brain tumors, they differ significantly in their presentation, treatment approaches, and expected outcomes. Understanding these distinctions is essential for accurate diagnosis and appropriate therapeutic planning. The biological heterogeneity of ependymoma, in particular, sets it apart from other glial tumors and demands tailored clinical strategies.
The Future of Ependymoma Research
The '-omics'-based approaches have been instrumental in identifying the primary drivers of ependymoma. Additional applications, such as epigenomics, proteomics, single-cell analysis, and metabolomics, may reveal other oncogenic drivers and offer further insights into the mechanisms of EPN-genesis. Advanced genomic sequencing might also uncover lesions or mutations that have been previously missed. By continuing partnerships between researchers and clinicians, and working toward international collaboration and shared access to samples, models, and data.
Expert Perspectives on Treatment
Experts in the ependymoma field consistently emphasize the importance of considering chemotherapy and targeted therapies as viable treatment options. Ependymomas are tumors of neuroectodermic origin, arising from ependymal cells that line the ventricles and central canal of the spinal cord, and are most common in children. Providers typically grade these tumors from 1 to 3 based on how quickly they spread, with grade 3 ependymomas classified as cancerous. Surgery to remove the tumor remains a cornerstone of treatment across all grades, though the role of adjuvant therapies continues to evolve.
Personalized Medicine and Novel Targets
Emerging trends in the ependymoma market center on personalized medicine and targeted therapies aimed at improving patient outcomes. A groundbreaking study published in Nature revealed that serotonin-producing neurons can regulate the growth of ependymoma brain tumors. Researchers discovered that ependymoma cells carry a serotonin transporter that imports serotonin into the cell, where it binds to histone H3, a protein tightly associated with DNA. This finding opens a novel therapeutic avenue, suggesting that targeting the serotonin signaling pathway could potentially control tumor growth.
Treatment Limitations and Unmet Needs
Ependymomas are glial tumors originating from ependymal cells in the brain and spinal cord, yet effective systemic treatment options remain limited. Current evidence indicates there is no clear indication that chemotherapy is useful in treating primary ependymomas in adults. For recurrent disease, treatment often shifts to palliative chemotherapy approaches, including platinum-based regimens, temozolomide, and/or etoposide. These limitations highlight a critical unmet need for more effective systemic therapies, particularly for adult patients and those with recurrent or refractory disease.
The Urgency of Progress
Researchers have acknowledged that there has been no meaningful impact on ependymoma patient survival in the last three decades, citing a poor understanding of the disease as a major factor. Pediatric ependymomas are thought to arise from radial glial cells lining the ventricular system, and studies using real-time PCR and loss of heterozygosity experiments on pediatric samples continue to search for candidate genes involved in tumor development. This stagnation in survival improvement underscores the critical need for deeper biological understanding and more effective therapeutic interventions.